16 completed, 1 recruiting, 1 unknown. 9 Phase 2, 6 Not applicable, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Not applicable | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Hvivo: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma Asthma (Diagnosis) | Recruiting | Hvivo | 250 | 2025-08-08 | 2025-09-24 | |
| Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3 - SARS-CoV-2 Infection | Early Phase 1 | Completed | Hvivo | 36 | 2024-12-02 | 2025-11-21 |
| Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain Influenza A H3N2 virus dose arm 1, Influenza A H3N2 virus dose arm 2, Influenza A H3N2 virus dose arm 3 - Influenza A H3N2 | Not applicable | Completed | Hvivo | 33 | 2024-09-11 | 2026-04-23 |
| Dose, Safety, and Pathogenicity of a New Influenza B Strain influenza B/Connecticut/1/21 virus part a dose arm 1, influenza B/Connecticut/1/21 virus part a dose arm 2, influenza B/Connecticut/1/21 virus part b dose 1 - Influenza B | Phase 2 | Unknown | Hvivo | 60 | 2023-10-03 | 2024-02-12 |
| Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain Infectious Titre 1, Infectious Titre 2, Infectious Titre 3 - Influenza A H1N1 | Not applicable | Completed | Hvivo | 70 | 2022-09-07 | 2023-09-13 |
| Study of SAB-176 in Healthy Adult Participants SAB-176, Placebo - Influenza A H1N1 | Phase 2 | Completed | SAb Biotherapeutics, Inc. | 62 | 2021-06-23 | 2025-01-22 |
| SARS-CoV-2 Human Challenge Characterisation Study SARS-CoV-2 Virus 1x10^1 TCID50, Remdesivir, SARS-CoV-2 Virus 1x10^2 TCID50 - Covid19, SARS-CoV Infection | Not applicable | Completed | Imperial College London | 36 | 2021-03-06 | 2025-05-16 |
| Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine MV-012-968, Placebo - RSV Infection | Phase 2 | Completed | Meissa Vaccines, Inc. | 60 | 2020-12-29 | 2022-08-04 |
| COVID-19 SARS-CoV-2 Screening Protocol Covid19 | Completed | Imperial College London | 36 | 2020-12-15 | 2024-08-13 | |
| Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults RSVPreF, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Completed | Hvivo | 70 | 2020-11-10 | 2024-08-07 |
| RSV Study in Adults 60 to 75 Years of Age Challenge virus RSV-A Memphis 37b - RSV Infection | Not applicable | Completed | Hvivo | 24 | 2019-03-12 | 2019-10-14 |
| A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16 PrEP-001, Placebo - Viral Upper Respiratory Tract Infection | Phase 2 | Completed | Prep Biopharm Limited | 102 | 2016-04-06 | 2018-11-09 |
| Study Examining PrEP-001 in Subjects With Asthma PrEP-001, G-004 - Asthma | Phase 2 | Completed | Hvivo | 60 | 2015-12-11 | 2017-09-29 |
| Study Examining PrEP-001 in Healthy Subjects PrEP-001, Placebo Comparator - Influenza A H3N2 | Phase 2 | Completed | Hvivo | 66 | 2015-09-16 | 2019-11-12 |
| Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model Infectious titre 1 (H3N2), Infectious titre 2 (H3N2), Infectious titre 3 (H3N2) - Influenza | Not applicable | Completed | Hvivo | 46 | 2014-01-01 | 2020-01-27 |
| Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge Titre 1, Titre 2, Titre 3 - Rhinovirus | Not applicable | Completed | Hvivo | 17 | 2013-01-01 | 2015-08-13 |
| Influenza Challenge Study in Healthy Volunteers High Titre Influenza virus, Medium - High Influenza virus, Medium Low Titre Influenza virus - Influenza | Phase 1 / Phase 2 | Completed | Hvivo | 24 | 2008-01-01 | 2016-04-21 |
| Development of an Intranasal Proteosome Influenza Vaccine Placebo Protesomal Vaccine, Experimental: Protesomal Vaccine 1 x 30 µg, Experimental: Protesomal Vaccine 2 x 30 µg - Influenza | Phase 1 / Phase 2 | Completed | Hvivo | 174 | 2002-01-01 | 2015-08-13 |
Influenza, Human (6) · COVID-19 (3) · Respiratory Syncytial Virus Infections (3) · Asthma (2) · Coronavirus Infections (2) · Orthomyxoviridae Infections (2) · Bronchial Spasm (1) · Cough (1) · Disease (1) · Dyspnea (1) · Inflammation (1) · Lymphoma, Follicular (1) · Severe Acute Respiratory Syndrome (1)
G004 compound (2) · Poly I-C (1) · remdesivir (1)
United Kingdom (14)
Alex Mann (2) · Alexandre Lima, MD-PhD (2) · John Efthimiou (2) · Bryan Muray, MD (1) · Bryan Murray, MD (1) · Chris Chiu (1) · Christopher Chiu (1) · Cyrus Ghobadi, MD (1) · Golam Kabir, MD (1) · Mariya Kalinova, MD (1) · Melissa Bevan, MBBS (1) · Oliver Medzihradsky, MD MPH MS (1) · Rob Lambkin-Williams, PhD (1) · Robert Lambkin-Williams, PhD (1) · Victoria Parker (1)
PMID 26761707, PMID 27280602, PMID 27936016, PMID 28005959, PMID 29567461, PMID 35361992, PMID 35731653, PMID 37307844, PMID 38898278, PMID 39364271, PMID 41354730